Lucas Le Roy

Mr. Lucas Le Roy

Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in Biomedical Optics Express
Verified
Journal Article
Closed access
PDF file
MDMatthieu Dubreuil
Matthieu Dubreuil
FTFlorine Tissier
Florine Tissier
LRLucas Le Roy
Lucas Le Roy
JPJean-Pierre Pennec
Jean-Pierre Pennec
SRSylvain Rivet
Sylvain Rivet
YGYann Le Grand
Yann Le Grand
Polarization-resolved second harmonic generation (P-SHG) microscopy is able to probe the sub-micrometer structural organization of myosin filaments within skeletal muscle. In this study, P-SHG microscopy was used to analyze the structural consequences of sepsis, which is the main cause of the critical illness polyneuromyopathy (CIPNM). Experiments conducted on two populations of rats demonstrated a significant difference of the anisotropy parameter between healthy and septic groups, indicating that P-SHG microscopy is promising for the diagnosis of CIPNM. The difference, which can be attributed to a change of myosin conformation at the sub-sarcomere scale, cannot be evidenced by classical SHG imaging.

8 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
LRLucas Le Roy
Lucas Le Roy
ALAnne Letondor
Anne Letondor
CRCloé Le Roux
Cloé Le Roux
AAAHMED AMARA
AHMED AMARA
Serge TimsitSerge Timsit
Serge Timsit
Ischemic stroke is the second leading cause of death worldwide. Following ischemic stroke, Neurovascular Unit (NVU) inflammation and peripheral leucocytes infiltration are major contributors to the extension of brain lesions. For a long time restricted to neurons, the 10 past years have shown the emergence of an increasing number of studies focusing on the role of Cyclin-Dependent Kinases (CDKs) on the other cells of NVU, as well as on the leucocytes. The most widely used CDKs inhibitor, (R)-roscovitine, and its (S) isomer both decreased brain lesions in models of global and focal cerebral ischemia. We previously showed that (S)-roscovitine acted, at least, by modulating NVU response to ischemia. Interestingly, roscovitine was shown to decrease leucocytes-mediated inflammation in several inflammatory models. Specific inhibition of roscovitine majors target CDK 1, 2, 5, 7, and 9 showed that these CDKs played key roles in inflammatory processes of NVU cells and leucocytes after brain lesions, including ischemic stroke. The data summarized here support the investigation of roscovitine as a potential therapeutic agent for the treatment of ischemic stroke, and provide an overview of CDK 1, 2, 5, 7, and 9 functions in brain cells and leucocytes during cerebral ischemia.

1 July 2020 in Brain Communications
Verified
Journal Article
Open access
PDF file
LRLucas Le Roy
Lucas Le Roy
AAAHMED AMARA
AHMED AMARA
CRCloé Le Roux
Cloé Le Roux
OBOzvan Bocher
Ozvan Bocher
ALAnne Létondor
Anne Létondor
Serge TimsitSerge Timsit
Serge Timsit
Stroke is a leading cause of acute death related in part to brain oedema, blood–brain barrier disruption and glial inflammation. A cyclin-dependant kinase inhibitor, (S)-roscovitine, was administered 90 min after onset on a model of rat focal cerebral ischaemia. Brain swelling and Evans Blue tissue extravasation were quantified after Evans Blue injection. Combined tissue Evans Blue fluorescence and immunofluorescence of endothelial cells (RECA1), microglia (isolectin-IB4) and astrocytes (glial fibrillary acidic protein) were analysed. Using a Student’s t-test or Mann–Whitney test, (S)-roscovitine improved recovery by more than 50% compared to vehicle (Mann–Whitney, P < 0.001), decreased significantly brain swelling by 50% (t-test, P = 0.0128) mostly in the rostral part of the brain. Main analysis was therefore performed on rostral cut for immunofluorescence to maximize biological observations (cut B). Evans Blue fluorescence decreased in (S)-roscovitine group compared to vehicle (60%, t-test, P = 0.049) and was further supported by spectrophotometer analysis (Mann–Whitney, P = 0.0002) and Evans Blue macroscopic photonic analysis (t-test, P = 0.07). An increase of RECA-1 intensity was observed in the ischaemic hemisphere compared to non-ischaemic hemisphere. Further study showed, in the ischaemic hemisphere that (S)-roscovitine treated group compared to vehicle, showed a decrease of: (i) endothelial RECA-1 intensity of about 20% globally, mainly located in the cortex (−28.5%, t-test, P = 0.03); (ii) Microglia’s number by 55% (t-test, P = 0.006) and modulated reactive astrocytes through a trend toward less astrocytes number (15%, t-test, P = 0.05) and astrogliosis (21%, t-test, P = 0.076). To decipher the complex relationship of these components, we analysed the six biological quantitative variables of our study by principal component analysis from immunofluorescence studies of the same animals. Principal component analysis differentiated treated from non-treated animals on dimension 1 with negative values in the treated animals, and positive values in the non-treated animals. Interestingly, stroke recovery presented a negative correlation with this dimension, while all other biological variables showed a positive correlation. Dimensions 1 and 2 allowed the identification of two groups of co-varying variables: endothelial cells, microglia number and Evans Blue with positive values on both dimensions, and astrocyte number, astrogliosis and brain swelling with negative values on dimension 2. This partition suggests different mechanisms. Correlation matrix analysis was concordant with principal component analysis results. Because of its pleiotropic complex action on different elements of the NeuroVascular Unit response, (S)-roscovitine may represent an effective treatment against oedema in stroke.

6 April 2026
Verified
Thesis
Closed access
LRLucas Le Roy
Lucas Le Roy
L’accident ischémique cérébral (AIC), est la 2nd cause de décès dans le monde. L’AIC est causé par l’obstruction d’un vaisseau sanguin cérébral provoquant, dans la région cérébrale concernée, l’arrêt de la circulation sanguine et une ischémie focale. Cette dernière est responsable de la mort des cellules cérébrales dans la région infarcie et de la formation d’un oedème cérébral pouvant mettre en péril la survie du patient. A la phase aiguë de l’AIC, l'inflammation de l'unité neurovasculaire (UNV) est l’un des principaux facteurs contribuant à l'extension des lésions cérébrales. Nous avons montré que la (S)-roscovitine, un inhibiteur des cyclines-dépendantes kinases (CDK), améliore la récupération neurologique et diminue le volume de l’infarctus dans des modèles d’ischémie focale chez le rat et la souris. Nous avons également observé que l’injection systémique de (S)-roscovitine diminue l’oedème cérébral dans un modèle d’ischémie focale chez le rat. Avec une approche intégrant plusieurs composants cellulaires de l’UNV et l’étude conjointe de ces différents composants par analyse en composante principale (ACP), nous avons montré que la (S)-roscovitine diminue l’oedème cérébral en protégeant la barrière matoencéphalique et en inhibant l’activation des microglies et des astrocytes. A partir de ces travaux, une revue de la littérature a été effectuée sur l’effet de la roscovitine sur l’UNV et les cellules immunes circulantes. Une méta-analyse des études sur la (S)-roscovitine est également présentée. Les travaux effectués sont en faveurs du développement de la (S)- roscovitine comme agent thérapeutique pour le traitement des AIC à la phase aiguë.